GT Biopharma (GTBP) Non-Current Assets (2010 - 2024)
GT Biopharma (GTBP) posted quarterly Non-Current Assets of $27000.0 for Q1 2024, down 81.88% year-over-year from $149000.0 in Q2 2023, and down 49.06% quarter-over-quarter from $53000.0 in Q4 2023.
GT Biopharma (GTBP) Non-Current Assets (2010 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Non-Current Assets for 14 consecutive years, with $27000.0 the latest figure, recorded in Q1 2024.
- In Q1 2024, Non-Current Assets fell 81.88% year-over-year to $27000.0; the TTM figure through Mar 2025 stood at $27000.0 (down 90.97% YoY), while the FY2023 annual figure was $53000.0, down 69.54% from the prior year.
- Non-Current Assets fell to $27000.0 in Q1 2024 per GTBP's latest filing, from $53000.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $246000.0 in Q1 2022 and bottomed at $27000.0 in Q1 2024.
- Historically, Non-Current Assets has averaged $131083.3 across 4 years, with a median of $115000.0 in 2020.
- Annual changes were most pronounced in 2020 — Non-Current Assets tumbled 99.64% — and 2023, when it plunged 39.43%.
- GT Biopharma's Non-Current Assets stood at $84000.0 in 2020, then jumped by 107.14% to $174000.0 in 2022, then sank by 69.54% to $53000.0 in 2023, then tumbled by 49.06% to $27000.0 in 2024.
- Business Quant data shows GTBP's Non-Current Assets at $27000.0 in Q1 2024, $53000.0 in Q4 2023, and $96000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 27,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Sep 30, 2023 | 96,000.00 |
| Jun 30, 2023 | 123,000.00 |
| Mar 31, 2023 | 149,000.00 |
| Dec 31, 2022 | 174,000.00 |
| Sep 30, 2022 | 199,000.00 |
| Jun 30, 2022 | 223,000.00 |
| Mar 31, 2022 | 246,000.00 |
| Sep 30, 2020 | 84,000.00 |
| Jun 30, 2020 | 92,000.00 |
| Mar 31, 2020 | 107,000.00 |
| Dec 31, 2019 | 122,000.00 |
| Sep 30, 2019 | 145,000.00 |
| Jun 30, 2019 | 25.42 Mn |
| Mar 31, 2019 | 25.46 Mn |
| Dec 31, 2018 | 25.31 Mn |
| Sep 30, 2018 | 25.29 Mn |
| Jun 30, 2018 | 253.92 Mn |
| Mar 31, 2018 | 254.46 Mn |